Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.02
Percentage change -0.10	%

Peers: REGN VRTX EXEL SRPT BMRN ALNY RARE IONS ADAP PBYI

| Held by: VTI IWM XBI VXF IWO VTWO SCHA IWN VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-4.05	Insider Own	9.78%	Shs Outstand	81.59M	Perf Week	6.76%
Market Cap	1.29B	Forward P/E	-	EPS next Y	-3.80	Insider Trans	0.00%	Shs Float	73.61M	Perf Month	25.71%
Income	-293.24M	PEG	-	EPS next Q	-1.01	Inst Own	103.46%	Short Float	14.54%	Perf Quarter	-1.10%
Sales	0.30M	P/S	4314.64	EPS this Y	-8.15%	Inst Trans	0.21%	Short Ratio	12.31	Perf Half Y	-16.39%
Book/sh	5.09	P/B	3.11	EPS next Y	6.71%	ROA	-45.42%	Short Interest	10.70M	Perf Year	25.31%
Cash/sh	7.80	P/C	2.03	EPS next 5Y	18.32%	ROE	-49.41%	52W Range	9.90 - 27.20	Perf YTD	-17.24%
Dividend Est.	-	P/FCF	-	EPS past 5Y	31.28%	ROIC	-46.77%	52W High	-41.68%	Beta	0.46
Dividend TTM	-	Quick Ratio	19.49	Sales past 5Y	-41.64%	Gross Margin	-334.44%	52W Low	60.24%	ATR (14)	0.75
Dividend Ex-Date	-	Current Ratio	19.49	EPS Y/Y TTM	10.13%	Oper. Margin	-111591.06%	RSI (14)	67.33	Volatility	3.14% 2.67%
Employees	143	Debt/Eq	0.04	Sales Y/Y TTM	4.86%	Profit Margin	-97100.00%	Recom	1.25	Target Price	37.80
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-34.47%	Payout	-	Rel Volume	0.55	Prev Close	15.88
Sales Surprise	41.45%	EPS Surprise	10.01%	Sales Q/Q	0.00%	Earnings	May 06 BMO	Avg Volume	869.19K	Price	15.86
SMA20	10.12%	SMA50	18.11%	SMA200	-10.92%	Trades		Volume	340,679	Change	-0.10%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$37 → $27
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy	$30 → $38
Jun-11-24	Initiated	Wolfe Research	Outperform	$29
Jun-06-24	Initiated	Goldman	Buy	$23
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral	$25 → $20
Jun-14-23	Resumed	Credit Suisse	Outperform	$51
Jun-14-23	Initiated	BTIG Research	Buy	$46
May-30-23	Initiated	RBC Capital Mkts	Outperform	$44
Apr-17-23	Initiated	Wells Fargo	Overweight	$46
Mar-30-23	Initiated	Stifel	Buy	$49
Dec-19-22	Initiated	Needham	Buy	$45
Dec-19-22	Initiated	Cowen	Outperform	$45
Dec-16-22	Initiated	Credit Suisse	Outperform	$51
Dec-01-22	Initiated	H.C. Wainwright	Buy	$35
Jun-23-22	Initiated	B. Riley Securities	Buy	$25
Nov-18-21	Initiated	SVB Leerink	Outperform	$32
Oct-12-21	Initiated	Evercore ISI	Outperform	$40
Jan-25-21	Initiated	Ladenburg Thalmann	Buy	$40

Show Previous Ratings

Jun-05-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-30-25 07:00AM	Viridian Therapeutics to Participate in Upcoming June Investor Conferences (Business Wire)
May-20-25 07:00AM	Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) (Business Wire) +7.80%
May-07-25 04:15PM	Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) (Business Wire)
May-06-25 08:10AM	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -8.31%
07:00AM	Loading…
07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results (Business Wire)
May-02-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-15-25 08:09AM	Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last? (Zacks)
Apr-07-25 07:00AM	Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors (Business Wire)
Mar-19-25 05:07PM	Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (SeekingAlpha)
Mar-10-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-06-25 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-08-25 07:00AM	Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease (Business Wire) -8.42%
Dec-17-24 07:40AM	Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints (TipRanks)
04:09PM	Loading…
Dec-16-24 04:09PM	Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen (Investor's Business Daily) +20.67%
09:28AM	Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease (Investor's Business Daily)
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease (Business Wire)
Dec-13-24 06:00PM	Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 (Business Wire)
Dec-04-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-12-24 07:00AM	Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data (Business Wire) -12.76%
Nov-05-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-24 11:25PM	Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock (Business Wire) +5.60%
Sep-10-24 04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (Business Wire) +32.14%
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (Business Wire)
Sep-09-24 04:01PM	Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 (Business Wire)
Sep-05-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.23%
Aug-08-24 08:15AM	Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-07-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-28-24 09:09AM	Goldman Sachs Predicts up to 165% Surge for These 2 Strong Buy Stocks (TipRanks)
08:00AM	Loading…
Jul-25-24 08:00AM	Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) (Business Wire)
Jul-08-24 10:38AM	3 Small-Cap Stocks With Explosive 2X Growth Potential (InvestorPlace)
Jul-03-24 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-27-24 09:48AM	Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-12-24 09:11AM	Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug (Zacks) -5.94%
Jun-11-24 06:00AM	Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease (Business Wire) +10.15%
Jun-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-31-24 08:00AM	Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences (Business Wire)
May-10-24 08:00AM	Viridian Therapeutics to Participate in Upcoming May Investor Conferences (Business Wire)
May-09-24 03:02AM	Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com) -6.64%
May-08-24 11:54AM	VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:36AM	Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements (GuruFocus.com)
08:25AM	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results (Business Wire)
May-03-24 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.62%
Apr-29-24 08:00AM	Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024 (Business Wire) +5.59%
Apr-04-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-24 08:00AM	Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (Business Wire)
Feb-28-24 09:55AM	How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81% (Zacks)
Feb-27-24 04:01PM	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-16-24 08:00AM	Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer (Business Wire)
Feb-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-17-24 10:00PM	Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock (Business Wire) -9.73%
04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (Business Wire)
Jan-08-24 08:00AM	Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference (Business Wire) +7.78%
Jan-04-24 08:00AM	Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-23 07:00AM	Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease (Business Wire) +9.52%
Nov-21-23 08:00AM	Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-23 05:00PM	Viridian Therapeutics Inc (VRDN) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com) +8.79%
04:01PM	Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
Nov-08-23 08:00AM	Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-03-23 08:00AM	Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology (Business Wire) +7.88%
Oct-30-23 08:30AM	Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing (Business Wire) +5.17%
Oct-26-23 08:00AM	Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease (Business Wire) +8.57%
Sep-25-23 08:00AM	Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors (Business Wire)
Sep-07-23 08:00AM	Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September (Business Wire)
Aug-08-23 04:01PM	Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (Business Wire) +5.69%
Aug-04-23 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jul-10-23 04:01PM	Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) (Business Wire) +5.06% -16.39%
Jul-06-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jun-13-23 08:00AM	Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society (Business Wire)
Jun-05-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-23 04:01PM	Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-23 08:00AM	Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections (GlobeNewswire)
May-04-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-23 08:00AM	Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023 (GlobeNewswire)
Apr-20-23 01:41PM	UPDATE Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology (GlobeNewswire)
08:00AM	Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology (GlobeNewswire)
Apr-16-23 09:50AM	TipRanks Perfect 10 List: 2 Top-Rated Stocks Potentially Undervalued by ~90% (TipRanks)
Apr-13-23 06:52AM	Daily Vickers Top Buyers & Sellers for 04/13/2023 (Argus Research)
Apr-12-23 08:00AM	Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer (GlobeNewswire)
Apr-04-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-08-23 07:00AM	Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates (GlobeNewswire) -10.48%
Mar-07-23 08:00AM	Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society (GlobeNewswire)
Mar-03-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-23 08:00AM	Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023 (GlobeNewswire)
Feb-28-23 08:00AM	Viridian Therapeutics to Participate in Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-07-23 08:00AM	Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference (GlobeNewswire)
Feb-06-23 07:00AM	Viridian Appoints Scott Myers as President and Chief Executive Officer (GlobeNewswire)
Feb-02-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-08-23 08:00AM	Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) (GlobeNewswire)
Jan-05-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-03-23 08:00AM	Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-22 07:00AM	Viridian Therapeutics Announces First Patient Enrolled in the THRIVE Phase 3 Trial in Patients With Thyroid Eye Disease (GlobeNewswire) +7.34%
Dec-07-22 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-28-22 07:00AM	Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-16-22 05:10AM	Viridian Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-14-22 07:01AM	Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates (GlobeNewswire)

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fairmount Funds Management LLC	Director	Jun 10 '25	Option Exercise	12.31	12,500	153,875	3,459,913	Jun 11 05:00 PM
Fairmount Funds Management LLC	Director	Jun 09 '25	Option Exercise	7.80	1,600	12,480	3,447,413	Jun 11 05:00 PM
Beetham Thomas W.	Chief Operating Officer	Sep 27 '24	Buy	23.41	5,000	117,050	6,000	Sep 30 07:12 PM
Mahoney Stephen F.	President and CEO	Sep 27 '24	Buy	23.33	21,400	499,262	21,400	Sep 30 07:10 PM
Fairmount Funds Management LLC	Director	Sep 13 '24	Buy	18.75	1,600,000	30,000,000	3,445,813	Sep 17 09:00 PM

Open in Screener

ZBIO

Zenas Biopharma Inc

Jun 16 • 02:01PM ET

9.96

Dollar change -0.37
Percentage change -3.58	%

Healthcare • Biotechnology • USA • NASD

ZBIO Zenas Biopharma Inc daily Stock Chart

Held by: VTI IWM VXF VTWO IWO SCHA IWN FESM IWC SBIO

Index	RUT	P/E	-	EPS (ttm)	-3.98	Insider Own	75.62%	Shs Outstand	41.82M	Perf Week	-16.44%
Market Cap	416.67M	Forward P/E	-	EPS next Y	-3.82	Insider Trans	0.11%	Shs Float	10.20M	Perf Month	2.26%
Income	-162.76M	PEG	-	EPS next Q	-1.04	Inst Own	32.96%	Short Float	47.61%	Perf Quarter	18.15%
Sales	15.00M	P/S	27.78	EPS this Y	65.55%	Inst Trans	4.32%	Short Ratio	24.53	Perf Half Y	8.73%
Book/sh	6.80	P/B	1.47	EPS next Y	6.69%	ROA	-85.03%	Short Interest	4.86M	Perf Year	-
Cash/sh	7.47	P/C	1.33	EPS next 5Y	31.82%	ROE	-115.47%	52W Range	5.83 - 26.25	Perf YTD	21.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROIC	-57.18%	52W High	-62.06%	Beta	-
Dividend TTM	-	Quick Ratio	6.47	Sales past 5Y	-	Gross Margin	99.15%	52W Low	70.84%	ATR (14)	1.04
Dividend Ex-Date	Dec 24, 2019	Current Ratio	6.47	EPS Y/Y TTM	-	Oper. Margin	-1157.59%	RSI (14)	46.98	Volatility	5.17% 6.97%
Employees	130	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-1085.07%	Recom	1.00	Target Price	32.14
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-10.71%	Payout	-	Rel Volume	0.38	Prev Close	10.33
Sales Surprise	499.99%	EPS Surprise	29.43%	Sales Q/Q	-	Earnings	May 15 BMO	Avg Volume	198.02K	Price	9.96
SMA20	-6.51%	SMA50	1.08%	SMA200	-14.44%	Trades		Volume	54,082	Change	-3.58%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-25	Initiated	Wedbush	Outperform	$35
Feb-04-25	Initiated	Wolfe Research	Outperform	$19
Dec-16-24	Initiated	H.C. Wainwright	Buy	$30
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$34
Oct-08-24	Initiated	Morgan Stanley	Overweight	$40
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$45
Oct-08-24	Initiated	Citigroup	Buy	$27

Jun-13-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -8.75%
Jun-02-25 04:00AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) +5.67%
May-29-25 07:05AM	Zenas BioPharma to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.34%
May-28-25 09:31AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) -12.59%
May-16-25 05:45AM	Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +7.49%
07:05AM	Loading…
May-15-25 07:05AM	Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +12.21%
May-06-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -19.71%
May-02-25 05:45AM	Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire)
Apr-29-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +12.56%
Apr-22-25 10:37AM	Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses (GlobeNewswire)
Apr-21-25 12:33PM	Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses (GlobeNewswire) +9.30%
Apr-17-25 04:20PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.08%
Apr-07-25 03:08PM	Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (Seeking Alpha)
07:05AM	Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-20-25 02:54PM	Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress (Benzinga)
11:41AM	Loading…
11:41AM	Zenas Bio rises as Wedbush launches with Outperform on lead asset (SeekingAlpha)
Mar-17-25 07:05AM	Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer (GlobeNewswire)
Feb-05-25 07:05AM	Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases (GlobeNewswire)
Jan-28-25 08:00AM	Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-17-24 06:25AM	Zenas BioPharma initiated with a Buy at H.C. Wainwright (TipRanks) +8.10%
Dec-12-24 07:35AM	Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley (TipRanks)
Nov-12-24 07:10AM	Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:05AM	Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
Nov-07-24 07:05AM	Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +7.63%
Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOULDER LEON O JR	Chief Executive Officer	Feb 18 '25	Buy	6.67	25,000	166,750	266,155	Feb 19 04:01 PM
Xiao Ting	Director	Feb 07 '25	Buy	7.76	10,000	77,600	47,000	Feb 11 04:20 PM
MOULDER LEON O JR	Chief Executive Officer	Dec 04 '24	Buy	9.98	45,000	449,100	241,155	Dec 04 09:03 PM
MOULDER LEON O JR	Chief Executive Officer	Dec 03 '24	Buy	10.76	25,000	269,000	196,155	Dec 04 09:03 PM
MOULDER LEON O JR	Chief Executive Officer	Nov 18 '24	Buy	15.00	7,500	112,500	168,655	Nov 20 05:20 PM
MOULDER LEON O JR	Chief Executive Officer	Nov 19 '24	Buy	14.57	2,500	36,425	171,155	Nov 20 05:20 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 18 '24	Buy	17.91	10,000	179,100	1,662,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 20 '24	Buy	18.45	5,000	92,270	1,672,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 19 '24	Buy	17.89	5,000	89,450	1,667,039	Sep 20 06:34 PM
Enavate Sciences GP, LLC	10% Owner	Sep 16 '24	Buy	17.00	882,353	15,000,001	3,761,359	Sep 18 04:15 PM
Lu Hongbo	Director	Sep 13 '24	Buy	17.00	58,823	999,991	58,823	Sep 17 07:52 PM
ENRIGHT PATRICK G	Director	Sep 16 '24	Buy	17.00	440,000	7,480,000	774,530	Sep 16 08:57 PM
Nunn Jason Raleigh	Director	Sep 16 '24	Buy	17.00	882,352	14,999,984	1,946,564	Sep 16 08:54 PM
Fairmount Funds Management LLC	Director	Sep 16 '24	Buy	17.00	300,000	5,100,000	1,604,891	Sep 16 08:54 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Sep 16 '24	Buy	17.00	2,235,294	37,999,998	1,946,564	Sep 16 08:51 PM

Dollar change -0.17
Percentage change -0.93	%

DNTH Dianthus Therapeutics Inc daily Stock Chart

Peers: VRTX REGN BIIB GILD AMGN MRNA BMY LLY PFE ABBV

| Held by: VTI IWM VXF XBI IWN VTWO SCHA AVSC IWC ITOT

Index	RUT	P/E	-	EPS (ttm)	-2.89	Insider Own	30.61%	Shs Outstand	32.13M	Perf Week	-0.27%
Market Cap	583.38M	Forward P/E	-	EPS next Y	-3.62	Insider Trans	0.00%	Shs Float	22.32M	Perf Month	-3.25%
Income	-100.73M	PEG	-	EPS next Q	-0.88	Inst Own	96.24%	Short Float	28.71%	Perf Quarter	-17.43%
Sales	6.52M	P/S	89.48	EPS this Y	-30.03%	Inst Trans	12.25%	Short Ratio	18.10	Perf Half Y	-27.44%
Book/sh	10.23	P/B	1.77	EPS next Y	-9.09%	ROA	-27.56%	Short Interest	6.41M	Perf Year	-27.90%
Cash/sh	8.19	P/C	2.22	EPS next 5Y	-16.60%	ROE	-28.73%	52W Range	13.36 - 32.27	Perf YTD	-16.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	40.14%	ROIC	-30.55%	52W High	-43.79%	Beta	1.38
Dividend TTM	-	Quick Ratio	15.99	Sales past 5Y	-	Gross Margin	93.29%	52W Low	35.73%	ATR (14)	1.26
Dividend Ex-Date	-	Current Ratio	15.99	EPS Y/Y TTM	51.03%	Oper. Margin	-1796.40%	RSI (14)	45.95	Volatility	5.39% 3.01%
Employees	78	Debt/Eq	0.00	Sales Y/Y TTM	189.31%	Profit Margin	-1544.02%	Recom	1.17	Target Price	51.40
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-53.91%	Payout	-	Rel Volume	0.24	Prev Close	18.31
Sales Surprise	44.13%	EPS Surprise	3.47%	Sales Q/Q	33.07%	Earnings	May 12 AMC	Avg Volume	353.98K	Price	18.14
SMA20	-0.89%	SMA50	-4.70%	SMA200	-21.20%	Trades		Volume	59,201	Change	-0.93%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-24	Initiated	TD Cowen	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform	$48
Jul-26-24	Initiated	Robert W. Baird	Outperform	$58
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy	$40
Feb-15-24	Initiated	Stifel	Buy	$44
Dec-26-23	Initiated	Jefferies	Buy	$22
Nov-22-23	Initiated	Wedbush	Outperform	$23
Oct-30-23	Initiated	Guggenheim	Buy	$45
Sep-28-23	Initiated	Raymond James	Outperform	$24
Aug-25-22	Downgrade	Goldman	Buy → Neutral	$2
Jan-06-22	Upgrade	Goldman	Neutral → Buy	$7 → $8
Aug-20-21	Resumed	Goldman	Neutral	$7
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral	$16 → $7
Jul-22-21	Reiterated	B. Riley Securities	Buy	$21 → $19
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight	$20
Jun-15-21	Initiated	BTIG Research	Buy	$20
May-18-21	Initiated	B. Riley Securities	Buy	$21
Jan-07-21	Initiated	Mizuho	Buy	$16
Jun-08-20	Upgrade	Goldman	Neutral → Buy	$15

Show Previous Ratings

May-29-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-25 04:10PM	Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors (GlobeNewswire)
May-12-25 05:10PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.18%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-07-25 05:35PM	Emergent Biosolutions (EBS) Q1 Earnings Top Estimates (Zacks)
07:00AM	Loading…
May-05-25 07:00AM	Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September (GlobeNewswire)
Apr-29-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Events (GlobeNewswire)
Apr-23-25 02:53PM	Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead (Seeking Alpha)
Apr-03-25 10:03AM	Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Mar-24-25 09:57AM	Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? (Zacks)
Mar-11-25 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results (GlobeNewswire) -6.33%
Mar-05-25 07:00AM	Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors (GlobeNewswire) +14.60%
Feb-26-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -6.32%
Jan-30-25 07:00AM	Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences (GlobeNewswire)
Jan-08-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
04:01PM	Loading…
Nov-07-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire)
Nov-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-15-24 07:00AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting (GlobeNewswire) +8.30%
Sep-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September (GlobeNewswire)
Aug-08-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
Jul-08-24 11:06AM	Dianthus (DNTH) Gains 18% in the Past Month: Here's Why (Zacks) +11.93%
Jun-28-24 11:30AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) (GlobeNewswire)
Jun-12-24 07:00AM	Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) (GlobeNewswire) +5.01%
May-30-24 04:30PM	Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -6.59%
May-09-24 10:56PM	DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-08-24 04:30PM	Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
May-03-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46% -7.29%
Apr-11-24 07:30AM	Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) +9.11%
Apr-05-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.02%
10:54PM	Loading…
Mar-21-24 10:54PM	DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +14.32%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results (GlobeNewswire)
Mar-07-24 04:30PM	Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-24 07:00AM	Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) (GlobeNewswire)
Feb-23-24 08:00AM	Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-31-24 04:05PM	Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire) +9.05%
Jan-22-24 07:30AM	Dianthus Therapeutics Announces $230 Million Private Placement (GlobeNewswire) +37.24%
Jan-02-24 08:30AM	Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.10%
Dec-14-23 07:04AM	DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 (InvestorPlace)
Nov-29-23 04:05PM	Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Nov-09-23 04:05PM	Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results (GlobeNewswire)
Sep-14-23 05:04PM	Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc (GuruFocus.com)
Aug-14-23 01:35PM	CEO of shuttered biotech Magenta Therapeutics makes leap to Flagship startup (American City Business Journals)
May-03-23 04:19PM	Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient Death (Benzinga) -14.29%
07:00AM	Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement (GlobeNewswire)
Mar-31-23 04:10PM	Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
06:09AM	The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics (Zacks)
Mar-27-23 10:20AM	Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-09-23 01:24PM	On eve of shutdown, Cambridge biotech loses 84% of staff, including 5 execs (American City Business Journals)
10:13AM	Magenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns Looms (Benzinga)
Feb-03-23 01:35PM	Magenta Therapeutics to shut down after patient death (American City Business Journals) +51.66%
Feb-02-23 04:05PM	Magenta Therapeutics to Explore Strategic Alternatives (GlobeNewswire)
05:58AM	The Petri Dish: Departed White House adviser returns to the Broad (American City Business Journals)
Jan-25-23 04:05PM	Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety (GlobeNewswire) +6.89% -11.09%
Dec-21-22 07:39AM	Magenta (MGTA) Down on Pipeline Update for Leukemia Drug (Zacks) -7.64%
Dec-20-22 11:20AM	Magenta Therapeutics Shares Crashes As Dose-Limiting Toxicities Observed In Lead Blood Cancer Study (Benzinga) -52.71%
09:00AM	Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial (GlobeNewswire)
Dec-13-22 05:56AM	Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting (Benzinga) -7.83%
Dec-12-22 04:30PM	Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates (GlobeNewswire)
08:00AM	Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial (GlobeNewswire)
Nov-03-22 09:01AM	Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
09:01AM	Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Nov-01-22 08:00AM	Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference (GlobeNewswire)
Oct-17-22 12:16PM	We Think Magenta Therapeutics (NASDAQ:MGTA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-23-22 09:15AM	Australian Billionaire Kerr Neilson is Selling These 15 Stocks (Insider Monkey)
Aug-17-22 08:00AM	Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors (GlobeNewswire)
Aug-04-22 08:00AM	Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Aug-02-22 08:00AM	Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-17-22 09:04AM	How Much Of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Do Institutions Own? (Simply Wall St.)
May-16-22 12:29PM	Magenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia Trial (Benzinga)
09:35AM	After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA) (Zacks)
08:00AM	Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights (Business Wire)
May-10-22 11:54AM	Here's Why We're Watching Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation (Simply Wall St.)
Apr-14-22 04:41PM	Stem cell startup cuts staff by 14% (American City Business Journals) -7.05% -14.29%
12:15PM	Magenta Therapeutics Trims R&D, Cuts Workforce (Benzinga)
08:00AM	Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway (Business Wire)
Mar-08-22 08:00AM	Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights (Business Wire) +7.06%
Mar-03-22 08:00AM	Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference (Business Wire)
Feb-07-22 09:35AM	What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares? (Simply Wall St.)
Jan-18-22 07:00AM	Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform (GlobeNewswire)
Jan-10-22 08:00AM	Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022 (Business Wire)
Jan-05-22 08:00AM	Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference (Business Wire) -6.50%
Dec-14-21 09:00AM	Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting (Business Wire)
Nov-10-21 06:20AM	Big Pharma Is Going Holiday Shopping. Who's Next? (Motley Fool)
Nov-08-21 09:24AM	Companies Like Magenta Therapeutics (NASDAQ:MGTA) Are In A Position To Invest In Growth (Simply Wall St.) -6.36%
Nov-04-21 09:10AM	Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights (Business Wire)
09:09AM	Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting (Business Wire)
Oct-04-21 08:00AM	Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer (Business Wire)
Sep-21-21 08:00AM	Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference (Business Wire)
Sep-15-21 08:00AM	Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial (Business Wire) +8.16%
Aug-09-21 06:20AM	How Much Of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Do Institutions Own? (Simply Wall St.)
Aug-05-21 08:00AM	Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights (Business Wire)
Aug-03-21 05:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (PR Newswire) -10.97%
08:00AM	Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August (Business Wire)
Aug-01-21 11:50AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (Newsfile)
Jul-30-21 09:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (ACCESSWIRE)
11:14AM	Were Hedge Funds Right About Magenta Therapeutics, Inc. (MGTA)? (Insider Monkey)
Jul-28-21 07:39PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (PR Newswire)
Jul-26-21 08:16PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (GlobeNewswire)
Jul-23-21 11:00AM	MGTA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Magenta Therapeutics, Inc. Investigation (ACCESSWIRE)

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Open in Screener

APGE

Apogee Therapeutics Inc

Jun 16 • 02:02PM ET

43.60

Dollar change -0.88
Percentage change -1.98	%

Healthcare • Biotechnology • USA • NASD

APGE Apogee Therapeutics Inc daily Stock Chart

Peers: VRTX REGN BMRN SRPT IONS ALNY QURE CRSP NTLA SGMO

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA VHT ITOT

Index	RUT	P/E	-	EPS (ttm)	-3.54	Insider Own	37.32%	Shs Outstand	46.04M	Perf Week	8.65%
Market Cap	2.60B	Forward P/E	-	EPS next Y	-5.51	Insider Trans	-0.17%	Shs Float	37.32M	Perf Month	7.28%
Income	-205.39M	PEG	-	EPS next Q	-1.09	Inst Own	88.24%	Short Float	27.20%	Perf Quarter	8.05%
Sales	0.00M	P/S	-	EPS this Y	-33.60%	Inst Trans	28.27%	Short Ratio	14.26	Perf Half Y	-10.60%
Book/sh	11.31	P/B	3.85	EPS next Y	-25.02%	ROA	-26.71%	Short Interest	10.15M	Perf Year	-1.60%
Cash/sh	8.62	P/C	5.06	EPS next 5Y	-21.59%	ROE	-27.85%	52W Range	26.20 - 63.50	Perf YTD	-3.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROIC	-30.15%	52W High	-31.34%	Beta	1.39
Dividend TTM	-	Quick Ratio	15.82	Sales past 5Y	-	Gross Margin	-	52W Low	66.41%	ATR (14)	2.46
Dividend Ex-Date	-	Current Ratio	15.82	EPS Y/Y TTM	-72.82%	Oper. Margin	-	RSI (14)	63.49	Volatility	3.39% 3.46%
Employees	196	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	93.88
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-48.72%	Payout	-	Rel Volume	1.25	Prev Close	44.48
Sales Surprise	-	EPS Surprise	21.84%	Sales Q/Q	-	Earnings	May 12 BMO	Avg Volume	711.84K	Price	43.60
SMA20	10.25%	SMA50	16.71%	SMA200	-0.51%	Trades		Volume	636,228	Change	-1.98%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Initiated	Citigroup	Buy	$95
Nov-25-24	Initiated	Canaccord Genuity	Buy	$89
May-10-24	Initiated	BofA Securities	Buy	$80
Dec-20-23	Initiated	BTIG Research	Buy	$43
Aug-08-23	Initiated	Wedbush	Outperform	$40
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Stifel	Buy	$34
Aug-08-23	Initiated	Jefferies	Buy	$29
Aug-08-23	Initiated	Guggenheim	Buy	$29

Jun-09-25 09:55AM	Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks)
May-29-25 07:30AM	Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-25 09:55AM	Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet (Zacks)
May-12-25 02:21PM	Why Is Apogee Therapeutics Stock Trading Higher On Monday? (Benzinga) +6.14%
06:05AM	Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results (GlobeNewswire)
06:00AM	Loading…
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4R Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
May-05-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade (Zacks)
May-01-25 08:00AM	Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference (GlobeNewswire)
Apr-14-25 08:04AM	Apogee Therapeutics: Engineering Biologic Dominance (Seeking Alpha)
Mar-26-25 05:50PM	Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? (InsiderMonkey)
Mar-03-25 12:16PM	Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial (Benzinga)
06:05AM	Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) (GlobeNewswire)
Mar-01-25 09:22AM	Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now? (Insider Monkey)
04:00PM	Loading…
Feb-28-25 04:00PM	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025 (GlobeNewswire)
Feb-25-25 07:30AM	Apogee Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-03-25 07:00AM	Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jan-30-25 03:44PM	Heres Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 (Insider Monkey) +5.41%
Jan-29-25 07:30AM	Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-10-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions (GlobeNewswire)
Dec-03-24 06:52AM	Apogee Therapeutics Advances in I&I Disease Treatments (TipRanks)
Dec-02-24 06:00AM	Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day (GlobeNewswire)
Nov-29-24 01:00PM	Apogee Therapeutics Announces Agenda for Virtual R&D Day (GlobeNewswire)
Nov-18-24 07:30AM	Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 (GlobeNewswire)
Nov-13-24 07:21AM	Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028 (TipRanks) -7.95%
Nov-12-24 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.14%
Nov-04-24 07:30AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-24-24 08:00AM	Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
Oct-16-24 07:00AM	Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting (GlobeNewswire)
04:50PM	Loading…
Oct-07-24 04:50PM	Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now (Insider Monkey)
Oct-04-24 01:03PM	Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc (GuruFocus.com)
Sep-12-24 07:00AM	Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit (GlobeNewswire)
Sep-09-24 07:00AM	Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer (GlobeNewswire)
Sep-07-24 01:45AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-24-24 01:30AM	Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-19-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire) +10.59%
Aug-12-24 06:30AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results (GlobeNewswire) +9.78%
Aug-10-24 01:00AM	Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-06-24 01:00AM	Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
May-28-24 07:30AM	Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD (GlobeNewswire)
May-23-24 07:30AM	Apogee Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-15-24 04:01PM	Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
May-13-24 01:53PM	APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:42AM	Apogee Therapeutics' Q1 Net Loss Widens (MT Newswires)
07:00AM	Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-10-24 10:13AM	BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target (MT Newswires)
May-08-24 01:28PM	Earnings Superstars: 3 Stocks Primed to Outperform This Quarter (InvestorPlace)
May-06-24 08:00AM	Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference (GlobeNewswire)
Apr-03-24 07:49AM	Paragons hub-and-spoke biotech model yields another reverse merger (BioPharma Dive)
Mar-28-24 11:01AM	Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why (Zacks)
Mar-25-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire) -5.01%
07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4R Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire)
Mar-12-24 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million (GlobeNewswire)
Mar-07-24 06:49PM	Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering (GlobeNewswire)
Mar-05-24 10:53PM	APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +42.07% +12.46%
04:23PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
04:16PM	Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water (Investor's Business Daily)
07:35AM	IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome (Investor's Business Daily)
07:35AM	IPO Stock Apogee Rockets On Solid Phase 1 Outcome (Investor's Business Daily)
06:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
06:00AM	Apogee data hint at potential for long-lasting eczema drug (BioPharma Dive)
06:00AM	Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days (GlobeNewswire)
Mar-04-24 04:01PM	Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024 (GlobeNewswire) +12.08%
Jan-02-24 07:30AM	Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-15-23 04:44AM	Apogee Therapeutics Inc Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
Nov-13-23 07:30AM	Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results (GlobeNewswire) +7.32%
Oct-30-23 08:00AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire) +5.77%
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace) -8.07%
Sep-27-23 08:42AM	Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire)
Sep-14-23 07:30AM	Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day (GlobeNewswire)
Aug-29-23 08:00AM	Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics (PR Newswire)
Aug-28-23 07:30AM	Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-21-23 07:30AM	Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board (GlobeNewswire)
Aug-10-23 02:29PM	FMR LLC Acquires New Stake in Apogee Therapeutics Inc (GuruFocus.com)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-23 07:30AM	Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
Aug-04-23 06:30PM	Apogee Therapeutics, Turnstone Biologics, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-02-23 07:30AM	Apogee Therapeutics to Participate in Upcoming August Investor Conferences (GlobeNewswire)
Jul-18-23 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dambkowski Carl	Chief Medical Officer	Jun 04 '25	Sale	36.96	2,725	100,716	241,723	Jun 06 08:01 PM
Dambkowski Carl	Chief Medical Officer	May 07 '25	Sale	35.75	2,725	97,419	244,448	May 09 08:01 PM
Dambkowski Carl	Chief Medical Officer	Apr 02 '25	Sale	36.22	3,860	139,801	247,173	Apr 04 08:01 PM
CARL DAMBKOWSKI	Officer	Apr 02 '25	Proposed Sale	35.61	9,310	331,529		Apr 02 04:23 PM
Dambkowski Carl	Chief Medical Officer	Mar 05 '25	Sale	30.48	1,590	48,463	251,033	Mar 07 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Mar 05 '25	Sale	30.15	10,000	301,511	1,292,987	Mar 07 08:01 PM
HENDERSON MICHAEL THOMAS	Officer	Mar 05 '25	Proposed Sale	30.15	10,000	301,501		Mar 05 01:46 PM
Dambkowski Carl	Chief Medical Officer	Feb 05 '25	Option Exercise	22.86	795	18,174	256,143	Feb 07 08:02 PM
Dambkowski Carl	Chief Medical Officer	Feb 05 '25	Sale	40.69	3,520	143,229	252,623	Feb 07 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Feb 05 '25	Sale	40.58	15,000	608,700	1,302,987	Feb 07 08:01 PM
HENDERSON MICHAEL THOMAS	Director	Feb 05 '25	Proposed Sale	40.58	15,000	608,728		Feb 05 02:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jan 31 '25	Option Exercise	22.86	8,500	194,310	1,317,987	Jan 31 08:00 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jan 08 '25	Sale	48.85	15,000	732,693	1,309,487	Jan 10 08:00 PM
HENDERSON MICHAEL THOMAS	Officer	Jan 08 '25	Proposed Sale	48.84	15,000	732,675		Jan 08 12:23 PM
Dambkowski Carl	Chief Medical Officer	Jan 02 '25	Option Exercise	22.86	1,360	31,090	259,433	Jan 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jan 02 '25	Sale	46.94	4,085	191,740	255,348	Jan 03 08:00 PM
McKenna Mark C.	Director	Dec 12 '24	Buy	49.54	20,000	990,775	20,000	Dec 16 06:00 AM
Dambkowski Carl	Chief Medical Officer	Dec 11 '24	Option Exercise	22.86	1,815	41,491	262,613	Dec 13 08:01 PM
Dambkowski Carl	Chief Medical Officer	Dec 11 '24	Sale	48.76	4,540	221,363	258,073	Dec 13 08:01 PM
CARL DAMBKOWSKI	Officer	Dec 11 '24	Proposed Sale	48.38	18,160	878,581		Dec 11 04:59 PM
Dambkowski Carl	Chief Medical Officer	Dec 04 '24	Sale	46.07	6,665	307,057	260,798	Dec 06 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 04 '24	Sale	46.58	15,000	698,654	1,324,487	Dec 06 08:01 PM
HENDERSON MICHAEL THOMAS	Officer	Dec 04 '24	Proposed Sale	46.58	15,000	698,709		Dec 04 11:12 AM
Dambkowski Carl	Chief Medical Officer	Nov 06 '24	Sale	59.12	6,665	394,041	267,463	Nov 08 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Nov 06 '24	Sale	59.22	15,000	888,320	1,339,487	Nov 08 08:01 PM
HENDERSON MICHAEL THOMAS	Officer	Nov 06 '24	Proposed Sale	59.23	15,000	888,388		Nov 06 11:39 AM
Dambkowski Carl	Chief Medical Officer	Oct 02 '24	Sale	56.26	6,665	374,954	274,128	Oct 04 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Oct 02 '24	Sale	56.23	40,000	2,249,307	1,354,487	Oct 04 08:01 PM
CARL DAMBKOWSKI	Officer	Oct 02 '24	Proposed Sale	57.31	16,010	917,533		Oct 02 04:20 PM
HENDERSON MICHAEL THOMAS	Officer	Oct 02 '24	Proposed Sale	56.23	40,000	2,249,176		Oct 02 02:34 PM
Dambkowski Carl	Chief Medical Officer	Sep 04 '24	Sale	47.56	6,665	316,969	280,793	Sep 06 08:03 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Sep 04 '24	Sale	47.62	40,000	1,904,841	1,394,487	Sep 06 08:02 PM
HENDERSON MICHAEL THOMAS	Officer	Sep 04 '24	Proposed Sale	47.62	40,000	1,904,848		Sep 04 01:35 PM
Henderson Jane	Chief Financial Officer	Aug 23 '24	Sale	48.26	6,000	289,560	200,871	Aug 23 08:05 PM
JANE V HENDERSON	Officer	Aug 23 '24	Proposed Sale	48.26	6,000	289,570		Aug 23 04:09 PM
Dambkowski Carl	Chief Medical Officer	Aug 07 '24	Sale	40.67	7,335	298,336	287,458	Aug 09 08:05 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Aug 07 '24	Sale	40.62	40,000	1,624,764	1,434,487	Aug 09 08:05 PM
HENDERSON MICHAEL THOMAS	Officer	Aug 07 '24	Proposed Sale	40.62	40,000	1,624,784		Aug 07 01:18 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jul 05 '24	Sale	37.26	15,000	558,900	1,474,487	Jul 05 08:01 PM
Dambkowski Carl	Chief Medical Officer	Jul 03 '24	Sale	37.60	5,995	225,418	294,793	Jul 05 08:01 PM

VRDN

Viridian Therapeutics Inc

ZBIO

Zenas Biopharma Inc

DNTH

Dianthus Therapeutics Inc

APGE

Apogee Therapeutics Inc

Upgrade your FINVIZ experience